Philip Komarnitsky

2.5k total citations · 1 hit paper
48 papers, 1.7k citations indexed

About

Philip Komarnitsky is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Philip Komarnitsky has authored 48 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 25 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Philip Komarnitsky's work include Lung Cancer Research Studies (11 papers), PARP inhibition in cancer therapy (9 papers) and Cancer therapeutics and mechanisms (8 papers). Philip Komarnitsky is often cited by papers focused on Lung Cancer Research Studies (11 papers), PARP inhibition in cancer therapy (9 papers) and Cancer therapeutics and mechanisms (8 papers). Philip Komarnitsky collaborates with scholars based in United States, Japan and Australia. Philip Komarnitsky's co-authors include Stephen Buratowski, Eun‐Jung Cho, Clyde L. Denis, Dan Chase, Y. C. Chiang, Bénédicte Michel, D. Ross Camidge, Toshimitsu Takagi, Matthew W. Dudley and Yasutaka Takase and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Philip Komarnitsky

47 papers receiving 1.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription

2000 864 citations Philip Komarnitsky, Stephen Buratowski et al. Genes & Development profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip Komarnitsky United States	19	1.3k	462	138	129	95	48	1.7k
Daniel Zingg Switzerland	18	1.0k 0.7×	473 1.0×	119 0.9×	359 2.8×	107 1.1×	33	1.6k
Sandra van Wilpe Netherlands	12	611 0.5×	364 0.8×	108 0.8×	135 1.0×	110 1.2×	25	1.2k
Kathleen A. Scorsone United States	15	674 0.5×	350 0.8×	63 0.5×	47 0.4×	103 1.1×	18	1.0k
Sander R. van Hooff Netherlands	16	528 0.4×	362 0.8×	94 0.7×	164 1.3×	72 0.8×	29	1.0k
Nick Loizos United States	18	523 0.4×	192 0.4×	146 1.1×	74 0.6×	118 1.2×	29	870
Mala Mani United States	11	1.1k 0.8×	413 0.9×	38 0.3×	132 1.0×	89 0.9×	15	1.4k
Beihai Jiang China	21	720 0.5×	426 0.9×	204 1.5×	149 1.2×	42 0.4×	58	1.2k
Lara Wohlbold Germany	16	1.1k 0.8×	332 0.7×	89 0.6×	92 0.7×	86 0.9×	20	1.4k
Y H Xu United States	5	570 0.4×	343 0.7×	98 0.7×	122 0.9×	141 1.5×	8	863

Countries citing papers authored by Philip Komarnitsky

Since Specialization

Citations

This map shows the geographic impact of Philip Komarnitsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Komarnitsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Komarnitsky more than expected).

Fields of papers citing papers by Philip Komarnitsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Komarnitsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Komarnitsky. The network helps show where Philip Komarnitsky may publish in the future.

Co-authorship network of co-authors of Philip Komarnitsky

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Komarnitsky. A scholar is included among the top collaborators of Philip Komarnitsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Komarnitsky. Philip Komarnitsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Camidge, D. Ross, Daniel Morgensztern, Rebecca S. Heist, et al.. (2021). Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma. Clinical Cancer Research. 27(21). 5781–5792. 60 indexed citations

Hann, Christine L., Timothy F. Burns, Afshin Dowlati, et al.. (2021). A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC. Journal of Thoracic Oncology. 16(9). 1582–1588. 30 indexed citations

Camidge, D. Ross, Jonathan W. Goldman, George W. Cole, et al.. (2020). 1414TiP Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort. Annals of Oncology. 31. S894–S894. 4 indexed citations

Ocampo, Clara B., Jun Wu, Jyotirmoy Dey, et al.. (2019). P2.01-19 Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET+ Non-Small Cell Lung Cancer: Trial in Progress. Journal of Thoracic Oncology. 14(10). S646–S646. 3 indexed citations

Atrafi, Florence, Harry J.M. Groen, Lauren A. Byers, et al.. (2018). A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clinical Cancer Research. 25(2). 496–505. 38 indexed citations

Berlin, Jordan, Ramesh K. Ramanathan, John H. Strickler, et al.. (2018). A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. British Journal of Cancer. 118(7). 938–946. 27 indexed citations

Горбунова, В. А., Thaddeus Beck, Ralf‐Dieter Hofheinz, et al.. (2018). Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.. Journal of Clinical Oncology. 36(15_suppl). 3543–3543. 1 indexed citations

Komarnitsky, Philip, et al.. (2017). A phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy. Annals of Oncology. 28. v542–v542. 4 indexed citations

Nishio, Shin, Munetaka Takekuma, Satoshi Takeuchi, et al.. (2017). Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Science. 108(11). 2213–2220. 21 indexed citations

10.

Atrafi, Florence, Harry J.M. Groen, Lauren A. Byers, et al.. (2017). Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results.. Journal of Clinical Oncology. 35(15_suppl). 8530–8530. 4 indexed citations

11.

Mok, Tony, Sarayut Lucien Geater, Wu‐Chou Su, et al.. (2016). A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. Journal of Thoracic Oncology. 11(10). 1736–1744. 41 indexed citations

12.

Gladkov, Oleg, Rodryg Ramlau, Piotr Serwatowski, et al.. (2015). Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer. Anti-Cancer Drugs. 26(10). 1061–1068. 18 indexed citations

13.

Tabernero, Josep, María Elena Elez, María Herranz‐López, et al.. (2014). A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases. Clinical Cancer Research. 20(10). 2793–2804. 30 indexed citations

14.

Mok, Tony, E.H. Tan, James Chih‐Hsin Yang, et al.. (2014). Efficacy Analysis of Gefitinib +/- Ficlatuzumab in Serum Proteomic Based Subgroups of Patients with Previously Untreated Lung Adenocarcinoma. Annals of Oncology. 25. iv70–iv70. 4 indexed citations

15.

Connor, Joseph P., Mihaela Cristea, Nancy Lewis, et al.. (2013). A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer. 13(1). 20–20. 35 indexed citations

16.

Jones, Barry, et al.. (2011). Anticancer activity of stabilized palifosfamide in vivo. Anti-Cancer Drugs. 23(2). 173–184. 5 indexed citations

17.

Tsimberidou, Apostolia M., Luis H. Camacho, Srđan Verstovšek, et al.. (2009). A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors. Clinical Cancer Research. 15(14). 4769–4776. 32 indexed citations

18.

Diaz, Zuanel, et al.. (2008). A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia. 22(10). 1853–1863. 38 indexed citations

19.

Komarnitsky, Philip, Bénédicte Michel, & Stephen Buratowski. (1999). TFIID-specific yeast TAF40 is essential for the majority of RNA polymerase II-mediated transcription in vivo. Genes & Development. 13(19). 2484–2489. 52 indexed citations

20.

Komarnitsky, Philip, et al.. (1998). ADR1-Mediated Transcriptional Activation Requires the Presence of an Intact TFIID Complex. Molecular and Cellular Biology. 18(10). 5861–5867. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact